Patricia Andrews Purchases 35,400 Shares of Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Patricia Andrews bought 35,400 shares of the stock in a transaction that occurred on Thursday, February 12th. The stock was bought at an average cost of C$1.18 per share, for a total transaction of C$41,772.00. Following the completion of the purchase, the director directly owned 78,128 shares of the company’s stock, valued at C$92,191.04. This represents a 82.85% increase in their ownership of the stock.

Oncolytics Biotech Stock Performance

Oncolytics Biotech Inc. has a 1 year low of C$0.44 and a 1 year high of C$2.08. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The stock has a 50-day moving average of C$14.90 and a two-hundred day moving average of C$13.11. The stock has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last issued its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) EPS for the quarter. On average, sell-side analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.